Navarro-Millán I, Rajan M, Lui GE, et al. - Researchers here determined differences in the use of conventional synthetic or biologic disease-modifying anti-rheumatic drugs (csDMARDs or bDMARDs, respectively) and long-term glucocorticoids (GC) or opioids by race/ethnicity among beneficiaries of the Social Security Disability Insurance (SSDI) with rheumatoid arthritis (RA) and < 65 years old. Cross-sectional analyses of Centers for Medicare and Medicaid Services claims data (2007, 2011, and 2014) yielded data of 12,931, 15,033, and 15,599 participants in 2007, 2011, and 2014, respectively. Observations are suggestive of racial and ethnic differences in the treatment of RA among beneficiaries of the SSDI. Among beneficiaries of the SSDI, the overall use of csDMARD without bDMARD were 31.1%, 30.3%, and 29.2%; 50.2%, 51.7%, and 53.8% used bDMARDs; 37.6%, 36.1%, and 34.4% used long-term GC; and 61.1%, 63.8%, and 63.7% used long-term opioids in years 2007, 2011, and 2014 respectively. Blacks vs Whites had higher use of csDMARDs without bDMARDs and lower use of bDMARDs. Hispanics vs Whites showed higher use of bDMARDs. Hispanics vs Whites displayed lower long-term GC use only in year 2014; no other difference in long-term GC use was noted. The highest use of long-term opioids was reported for White patients.